Heart valve leakage study in a type of amyloid heart disease
Part of Heart & circulation clinical trials.
This study looks at how common and how serious heart valve leaks are in people with transthyretin amyloid cardiomyopathy (a condition where abnormal protein builds up in the heart). The goal is to better understand these leaks and how they affect long-term health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM).
- You had a detailed heart ultrasound (echocardiogram) within 6 months before or after your diagnosis.
- You are 18 years or older.
- You are willing to take part in the study and give your consent.
- You do not have severe aortic valve disease that needs treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clip procedure to fix a leaky heart valve in people who also have a heart condition called ATTR-CM, which can cause heart failure. The clip is placed without open-heart surgery to help improve symptoms and quality of life.
This study looks at tiny particles called extracellular vesicles in the blood of people with a specific type of heart amyloidosis. It aims to find better ways to track the disease and predict outcomes.
This research study checks a small sample of heart tissue during pacemaker or defibrillator placement to see if amyloidosis, a condition where abnormal proteins build up in organs, is present. It aims to find amyloidosis earlier so treatment can start sooner.
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
This trial studies people with atrial fibrillation and moderate-to-severe leakiness in the mitral and tricuspid valves in the heart. It likely aims to improve symptoms and heart function by better addressing how these valve leaks happen.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
Hear when a new ATTR-CM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.